There's some interesting perspectives on the problems Dendreon is facing with gaining market penetration for Provenge in here:
http://www.ft.com/intl/cms/s/2/d9495d4c-d26f-11e0-9137-00144feab49a,dwp_uuid=e8477cc4-c820-11db-b0dc-000b5df10621.html#axzz1WXNZUK7I
Note the comments of practising oncologists - very significant. It is the clinicians who ultimately determine how much of a therapy is used.
Anyone who has been around Prima for a while knows how closely aligned the technology is and also how the market reference PRR responds to significant happenings in Dendreon.
I am sure that MR and Co are watching very carefully the fallout around Dendreon and will be building an approach to marketing cVac which will try to avoid falling into the same traps.
And if that's not enough to motivate them, I'm sure this will:
http://pr-usa.net/index.php?option=com_content&task=view&id=865815&Itemid=34
- Forums
- ASX - By Stock
- learning curve
There's some interesting perspectives on the problems Dendreon...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
34.3¢ |
Change
0.003(0.74%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.5¢ | 34.8¢ | 33.5¢ | $231.1K | 674.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 123567 | 34.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.5¢ | 350893 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 119801 | 0.340 |
11 | 178918 | 0.335 |
10 | 173242 | 0.330 |
13 | 92243 | 0.325 |
10 | 176459 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.345 | 363518 | 16 |
0.350 | 330138 | 21 |
0.355 | 134791 | 9 |
0.360 | 144288 | 9 |
0.365 | 216831 | 11 |
Last trade - 14.31pm 29/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |